These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 27646474)

  • 1. iRGD-mediated core-shell nanoparticles loading carmustine and O
    Liu C; Yao S; Li X; Wang F; Jiang Y
    J Drug Target; 2017 Mar; 25(3):235-246. PubMed ID: 27646474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cationic core-shell nanoparticles with carmustine contained within O⁶-benzylguanine shell for glioma therapy.
    Qian L; Zheng J; Wang K; Tang Y; Zhang X; Zhang H; Huang F; Pei Y; Jiang Y
    Biomaterials; 2013 Nov; 34(35):8968-78. PubMed ID: 23953782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells.
    Gu G; Gao X; Hu Q; Kang T; Liu Z; Jiang M; Miao D; Song Q; Yao L; Tu Y; Pang Z; Chen H; Jiang X; Chen J
    Biomaterials; 2013 Jul; 34(21):5138-48. PubMed ID: 23582684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
    Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
    Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment.
    Zhang Z; Qian H; Huang J; Sha H; Zhang H; Yu L; Liu B; Hua D; Qian X
    Int J Nanomedicine; 2018; 13():4961-4975. PubMed ID: 30214200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
    Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
    Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment.
    Zhong Y; Su T; Shi Q; Feng Y; Tao Z; Huang Q; Li L; Hu L; Li S; Tan H; Liu S; Yang H
    Int J Nanomedicine; 2019; 14():8543-8560. PubMed ID: 31802868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploiting macrophages as targeted carrier to guide nanoparticles into glioma.
    Pang L; Qin J; Han L; Zhao W; Liang J; Xie Z; Yang P; Wang J
    Oncotarget; 2016 Jun; 7(24):37081-37091. PubMed ID: 27213597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioma-homing peptide with a cell-penetrating effect for targeting delivery with enhanced glioma localization, penetration and suppression of glioma growth.
    Gao H; Yang Z; Zhang S; Cao S; Pang Z; Yang X; Jiang X
    J Control Release; 2013 Dec; 172(3):921-8. PubMed ID: 24120853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability.
    Gao F; Zhang J; Fu C; Xie X; Peng F; You J; Tang H; Wang Z; Li P; Chen J
    Int J Nanomedicine; 2017; 12():4147-4162. PubMed ID: 28615942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. iRGD-Guided Silica/Gold Nanoparticles for Efficient Tumor-Targeting and Enhancing Antitumor Efficacy Against Breast Cancer.
    Hou X; Chen Q; Fang Y; Zhang L; Huang S; Xu M; Ren Y; Shi Z; Wei Y; Li L
    Int J Nanomedicine; 2024; 19():8237-8251. PubMed ID: 39157735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical ocular delivery to laser-induced choroidal neovascularization by dual internalizing RGD and TAT peptide-modified nanoparticles.
    Chu Y; Chen N; Yu H; Mu H; He B; Hua H; Wang A; Sun K
    Int J Nanomedicine; 2017; 12():1353-1368. PubMed ID: 28260884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pep-1&borneol-Bifunctionalized Carmustine-Loaded Micelles Enhance Anti-Glioma Efficacy Through Tumor-Targeting and BBB-Penetrating.
    Guo X; Wu G; Wang H; Chen L
    J Pharm Sci; 2019 May; 108(5):1726-1735. PubMed ID: 30537472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D,L-lactic acid) nanoparticles.
    Kang C; Yuan X; Zhong Y; Pu P; Guo Y; Albadany A; Yu S; Zhang Z; Li Y; Chang J; Sheng J
    Technol Cancer Res Treat; 2009 Feb; 8(1):61-70. PubMed ID: 19166243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors.
    Byeon HJ; Thao le Q; Lee S; Min SY; Lee ES; Shin BS; Choi HG; Youn YS
    J Control Release; 2016 Mar; 225():301-13. PubMed ID: 26826308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and in vitro evaluation of carmustine delivery platform: A hypoxia-sensitive anti-drug resistant nanomicelle with BBB penetrating ability.
    Li D; Ren T; Wang X; Xiao Z; Sun G; Zhang N; Zhao L; Zhong R
    Biomed Pharmacother; 2023 Nov; 167():115631. PubMed ID: 37804814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin delivery to 3D multicellular spheroids and tumors based on boronic acid-rich chitosan nanoparticles.
    Wang X; Zhen X; Wang J; Zhang J; Wu W; Jiang X
    Biomaterials; 2013 Jun; 34(19):4667-79. PubMed ID: 23537667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and evaluation of tumour microenvironment response multistage nanoparticles for epirubicin delivery and deep tumour penetration.
    Dai J; Han S; Ju F; Han M; Xu L; Zhang R; Sun Y
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):860-873. PubMed ID: 29771149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. iNGR-modified PEG-PLGA nanoparticles that recognize tumor vasculature and penetrate gliomas.
    Kang T; Gao X; Hu Q; Jiang D; Feng X; Zhang X; Song Q; Yao L; Huang M; Jiang X; Pang Z; Chen H; Chen J
    Biomaterials; 2014 May; 35(14):4319-32. PubMed ID: 24565520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
    Quinn JA; Pluda J; Dolan ME; Delaney S; Kaplan R; Rich JN; Friedman AH; Reardon DA; Sampson JH; Colvin OM; Haglund MM; Pegg AE; Moschel RC; McLendon RE; Provenzale JM; Gururangan S; Tourt-Uhlig S; Herndon JE; Bigner DD; Friedman HS
    J Clin Oncol; 2002 May; 20(9):2277-83. PubMed ID: 11980998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.